The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Quick Searches
Selecting one or more of the options below will update the content below.
- Observational StudyIn-Person
What is this Study about?
We aim to explore how gender, social, and sensory factors influence the experiences of people who are living with cognitive decline and their spouses. We will complete a 90-min in-person interview with dyads (people living with cognitive decline and their spouses). Individuals are eligible to participate if the older person or their spouse lives with memory problems, experiences hearing impairment, and if the dyad has ever lived together in the community. Results may help identify ways to support the well-being of individuals with cognitive impairment and their spouses, paving the way for future studies.
Eligibility Criteria
Individuals are eligible to participate if the older person or their spouse lives with memory problems, experiences hearing impairment, and if the dyad has ever lived together in the community. Ability to speak English.
Recruitment End Date
- Observational StudyIn-Person
What is this Study about?
Early detection of brain changes is crucial to prevent cognitive decline and dementia. This study uses electroencephalography (EEG) to record the brain's electrical signals during simple tasks, with the hope of validating a measure that can improve early detection of Alzheimer’s disease.
We are recruiting 150 individuals with mild memory issues and mild dementia at Baycrest in Toronto and Bruyère in Ottawa. In a separate study we are also recruiting older adults with no memory problems. The results of both studies together will help us determine if our new EEG measure can detect abnormal changes in brain health early on and if it can help predict future cognitive changes. We hope that this new test will be used in the clinic to identify individuals who may benefit the most from early treatment and interventions.
Eligibility Criteria
- Are between 60 and 85 years of age
- Have a diagnosis of amnestic mild cognitive impairment or mild dementia due to Alzheimer’s
- Have normal vision (with visual aids, if needed) and no other serious health issues
- Ability to speak English
Recruitment End Date
- Observational StudyOnline
What is this Study about?
The purpose of this study is to explore the experiences of receiving a dementia diagnosis in northwestern Ontario healthcare systems in order to improve the diagnosis process for others who may be diagnosed in the future, and physicians/health care providers who diagnose people with dementia.
Eligibility Criteria
• Are practicing medicine in northwestern Ontario
• Have experience diagnosing people with dementia
• Have practiced for a minimum of 1 year
• Speak English
OR
• Have been diagnosed with dementia between 1-5 years
• Lived in northwestern Ontario at the time of diagnosis
• Are currently living in northwestern Ontario
• Speak English
Recruitment End Date
- Observational StudyOnline
What is this Study about?
Surveying opinions on how to improve diversity in dementia research.
Eligibility Criteria
You are eligible to participate if you are:
1) Involved in dementia research or services
AND / OR
2) from an underserved group* in dementia research.
3)Aged 19 +
3)Able to complete the web-based survey in one of the following languages: English, French, Chinese (simplified), Punjabi, Inuktitut.
*Underserved groups in dementia research include: Racial/ethnic minorities (i.e., South Asian, Chinese, Black, Filipino, Arab, Latin American, Southeast Asian, West Asian, Korean, Japanese, or other racial/ethnic minority) Indigenous populations (i.e., First Nations, Inuit, Métis, or other Indigenous group), Sexual/gender minorities (i.e., the LGBTQ2S+ community), Individuals living in rural and/or remote communities, Individuals living with a disability, Individuals with low social and economic conditions.
Recruitment End Date
- Observational StudyOnline & In-Person
What is this Study about?
A dementia diagnosis impacts the cognitive, functional, and physical abilities of those diagnosed, which will influence their ability to perform activities of daily living including meal preparation and eating. Persons living with dementia can experience a range of difficulties while eating that will impact their ability to consume adequate food and fluids, which include but are not limited to swallowing, chewing, and self-feeding difficulties. Consequently, persons living with dementia are at increased risk of malnutrition and negative health outcomes. The objective of this study is to understand the experience of persons’ living with dementia or diagnosed memory problems and/or their caregivers in managing eating challenges and swallowing problems in the community.
Eligibility Criteria
You are eligible to participate if you:
- Speak English
- A person with memory problems experiencing eating challenges or swallowing problems in the community
- OR if you are or were a caregiver to a person with memory problems with eating challenges or swallowing problems.Recruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Eligibility Criteria
Age 50 - 85
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Must have a study partnerRecruitment End Date
- Clinical TrialIn-Person
What is this Study about?
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Eligibility Criteria
60+
Diagnosis of Alzheimer's disease
Must have a study partnerRecruitment End Date
- Clinical TrialIn-Person
What is this Study about?
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
Eligibility Criteria
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
Recruitment End Date
- Observational StudyIn-Person
What is this Study about?
Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.
Eligibility Criteria
Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.
Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.
Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.
Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.
Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.
Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.
Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.
Have not undergone any significant head trauma or surgery in the past 6 months.
Are not pregnant or planning to become pregnant during the duration of the study.
Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.
Ability to speak English and French
Recruitment End Date
Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: [email protected]
Charity registration number: 11878 4925 RR0001
Follow us: